Actinium Pharmaceuticals

Sandesh Seth, CEO & Chairman of the Board of Actinium Pharmaceuticals (NASDAQ: ATNM), was recently a guest on Benzinga’s All-Access. Actinium is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision...

Patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) have a poor prognosis, and treatment remains challenging. It is a devastating disease that still represents a major unmet medical need, and for the majority of r/r patients, allogeneic hematopoietic stem cell...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. As science advances in terms of finding new treatments for unmet medical needs, certain approaches are not appropriate for specific types...